Results 41 to 50 of about 83,483 (295)

A machine learning and network framework to discover new indications for small molecules.

open access: yesPLoS Computational Biology, 2020
Drug repurposing, identifying novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapies to patients faster. However, most repurposing discoveries have been led by anecdotal observations (e.g.
Coryandar Gilvary   +5 more
doaj   +1 more source

Drug Repurposing for Rare Orphan Diseases Using Machine Learning Techniques

open access: yesProceedings of the International Florida Artificial Intelligence Research Society Conference, 2022
New drug discovery is a time-consuming and costly process. Several drugs have been in clinical trials for a very long period. Finding a new target for existing medications can be an effective strategy to reduce the lengthy and costly drug development ...
Rajesh Manicavasaga   +3 more
doaj   +1 more source

Pharmacology and clinical drug candidates in redox medicine [PDF]

open access: yes, 2015
SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I   +11 more
core   +3 more sources

Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]

open access: yes, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core   +1 more source

Big data and data repurposing – using existing data to answer new questions in vascular dementia research [PDF]

open access: yes, 2017
Introduction: Traditional approaches to clinical research have, as yet, failed to provide effective treatments for vascular dementia (VaD). Novel approaches to collation and synthesis of data may allow for time and cost efficient hypothesis generating ...
A Abdul-Rahim   +56 more
core   +8 more sources

A novel drug repurposing approach for non-small cell lung cancer using deep learning.

open access: yesPLoS ONE, 2020
Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far
Bingrui Li   +6 more
doaj   +1 more source

A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases

open access: yesLife, 2021
The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks.
Md. Mohaiminul Islam   +2 more
doaj   +1 more source

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing [PDF]

open access: yes, 2019
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery.
Baldwin, Nicole E.   +4 more
core   +1 more source

The newfound relationship between extrachromosomal DNAs and excised signal circles

open access: yesFEBS Letters, EarlyView.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors

open access: yesPharmacology Research & Perspectives
Cancer medicines often have narrow therapeutic windows; toxicity can be severe and sometimes fatal, but inadequate dose intensity reduces efficacy and survival.
Jennifer H. Martin   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy